Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients

• Status: Completed
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Three month treatment of acute VTE with Fragmin in pediatric cancer patients

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Dalteparin; Heparin, Low-Molecular-Weight; Tinzaparin

Criteria

Inclusion Criteria:

-

Exclusion Criteria:

-